ArticleJournal of gastric cancer2026
Optimizing Postoperative Management in Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter Retrospective Study.
Article in Journal of gastric cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeThe benefit of chemotherapy in locally advanced gastroesophageal cancer with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) remains uncertain. This study aimed to identify optimal postoperative management strategies for dMMR/MSI-H gastric or gastroesophageal junction (EGJ) adenocarcinoma. MATERIALS AND
methodsPatients with pathologically confirmed stage II-IVA dMMR/MSI-H gastric or EGJ adenocarcinoma who underwent D2 gastrectomy between 2015 and 2022 were retrospectively enrolled from 4 centers. Postoperative management strategies included observation, chemotherapy, immune checkpoint inhibitors (ICIs), or ICIs combined with chemotherapy (ICI-chemo). The primary endpoint was 2-year event-free survival (EFS), and the secondary endpoints were EFS and overall survival (OS).
resultsA total of 156 patients were included in the analysis. The highest 2-year EFS was observed in the ICI-chemo group (87.5%), followed by the observation group (86.7%) and the ICI monotherapy group (86.5%), whereas chemotherapy alone yielded the lowest rate (75.7%). Patients with earlier-stage disease had significantly lower risks of progression (hazard ratio [HR], 0.29; 95% confidence interval [CI], 0.16-0.53) and death (HR, 0.30; 95% CI, 0.14-0.64). EFS improved progressively from chemotherapy to observation and further to ICI-containing regimens across stages. In stage III-IVA disease, ICI monotherapy significantly improved OS compared with chemotherapy (HR, 0.28; P=0.038), with a favorable trend observed for ICI-chemo (HR, 0.32).
conclusionsPathological stage is an independent prognostic factor in resectable dMMR/MSI-H gastric and EGJ adenocarcinoma. Adjuvant chemotherapy alone demonstrated limited benefit, whereas ICI-based regimens were associated with improved outcomes, supporting their use in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.